Shunqiang Li

8.0k total citations · 1 hit paper
61 papers, 2.3k citations indexed

About

Shunqiang Li is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shunqiang Li has authored 61 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 31 papers in Oncology, 18 papers in Molecular Biology and 12 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shunqiang Li's work include Advanced Breast Cancer Therapies (12 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer-related Molecular Pathways (11 papers). Shunqiang Li is often cited by papers focused on Advanced Breast Cancer Therapies (12 papers), HER2/EGFR in Cancer Research (11 papers) and Cancer-related Molecular Pathways (11 papers). Shunqiang Li collaborates with scholars based in United States, China and France. Shunqiang Li's co-authors include Matthew J. Ellis, X. Cynthia, Shyam M. Kavuri, Li Ding, Ron Bose, Wei Shen, Nicholas Goel, Elaine R. Mardis, Daniel C. Koboldt and Adam B. Aronson and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Investigation and Nature Medicine.

In The Last Decade

Shunqiang Li

56 papers receiving 2.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer

2012 600 citations Ron Bose, Shyam M. Kavuri et al. Cancer Discovery profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shunqiang Li United States	20	938	895	486	463	387	61	2.3k
Gina G. Chung United States	25	1.5k 1.6×	1.3k 1.5×	510 1.0×	911 2.0×	304 0.8×	68	3.2k
Jasgit C. Sachdev United States	23	1.6k 1.7×	1.7k 1.9×	558 1.1×	947 2.0×	183 0.5×	126	3.4k
Joon Jeong South Korea	33	1.9k 2.0×	1.1k 1.2×	677 1.4×	1.7k 3.7×	514 1.3×	274	4.0k
Debasish Tripathy United States	21	1.7k 1.8×	778 0.9×	484 1.0×	1.2k 2.5×	538 1.4×	54	2.8k
Giuseppe Floris Belgium	28	1.1k 1.2×	793 0.9×	670 1.4×	642 1.4×	126 0.3×	118	2.6k
Gilbert Spizzo Austria	29	1.7k 1.8×	2.1k 2.3×	488 1.0×	723 1.6×	351 0.9×	70	3.8k
Jermaine Coward Australia	23	1.2k 1.3×	704 0.8×	380 0.8×	354 0.8×	126 0.3×	87	2.3k
Elisabetta Munzone Italy	31	2.4k 2.6×	611 0.7×	765 1.6×	1.4k 3.0×	302 0.8×	129	3.3k
Jianbo Wang China	29	800 0.9×	1.2k 1.4×	612 1.3×	768 1.7×	192 0.5×	125	2.9k

Countries citing papers authored by Shunqiang Li

Since Specialization

Citations

This map shows the geographic impact of Shunqiang Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shunqiang Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shunqiang Li more than expected).

Fields of papers citing papers by Shunqiang Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shunqiang Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shunqiang Li. The network helps show where Shunqiang Li may publish in the future.

Co-authorship network of co-authors of Shunqiang Li

This figure shows the co-authorship network connecting the top 25 collaborators of Shunqiang Li. A scholar is included among the top collaborators of Shunqiang Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shunqiang Li. Shunqiang Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhou, Shuyan, Chunyan Hou, Changmin Peng, et al.. (2025). Stabilization of RUNX1 Induced by O-GlcNAcylation Promotes PDGF-BB–Mediated Resistance to CDK4/6 Inhibitors in Breast Cancer. Cancer Research. 85(9). 1708–1724. 2 indexed citations

Jaehnig, Eric J., Meenakshi Anurag, Jonathan T. Lei, et al.. (2025). NF1-depleted ER ⁺ breast cancers are differentially sensitive to CDK4/6 inhibitors. Science Translational Medicine. 17(813). eadq5492–eadq5492.

Zhou, Kaixuan, Yonghao Zhao, Qingzhong Mao, Shunqiang Li, & Jizi Liu. (2025). Enhanced mechanical and electrical properties of Cu-Ni-Be alloys through rotary swaging and aging treatment. Journal of Material Science and Technology. 236. 1–18. 1 indexed citations

Li, Shunqiang, et al.. (2025). Achieving higher strength without sacrificing any ductility in a medium carbon steel via a controllable heterostructured composite strategy. Materials Science and Engineering A. 945. 149007–149007.

Zhou, Kaixuan, Yonghao Zhao, Qingzhong Mao, et al.. (2024). Simultaneously enhancing strength and ductility of coarse grain Cu–Al alloy via a macro dual-cable structure. Composites Part B Engineering. 276. 111371–111371. 18 indexed citations

Zhou, Kaixuan, Yonghao Zhao, Qingzhong Mao, et al.. (2024). Fractal structure and nano-precipitates break comprehensive performance limits of CuCrZr alloys. Nano Today. 56. 102234–102234. 14 indexed citations

Gou, Xuxu, Meenakshi Anurag, Jonathan T. Lei, et al.. (2023). Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer. Cancer Research. 83(19). 3237–3251. 4 indexed citations

Roy, Sudipta, Timothy Whitehead, Jingqin Luo, et al.. (2021). Deep Learning Segmentation of Triple-Negative Breast Cancer (TNBC) Patient Derived Tumor Xenograft (PDX) and Sensitivity of Radiomic Pipeline to Tumor Probability Boundary. Cancers. 13(15). 3795–3795. 26 indexed citations

Mazumder, Aloran, Rashi Kalra, Shunqiang Li, et al.. (2021). Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer. Nature Communications. 12(1). 2940–2940. 13 indexed citations

10.

Roy, Sudipta, Timothy Whitehead, Shunqiang Li, et al.. (2021). Co-clinical FDG-PET radiomic signature in predicting response to neoadjuvant chemotherapy in triple-negative breast cancer. European Journal of Nuclear Medicine and Molecular Imaging. 49(2). 550–562. 56 indexed citations

11.

Wang, Xian, Jamunarani Veeraraghavan, Lanfang Qin, et al.. (2021). Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer. Clinical Cancer Research. 27(9). 2648–2662. 8 indexed citations

12.

Chen, Baihong, et al.. (2020). A Novel Identification Method for Apple (Malus domestica Borkh.) Cultivars Based on a Deep Convolutional Neural Network with Leaf Image Input. Symmetry. 12(2). 217–217. 16 indexed citations

13.

Liu, Shuying, Shunqiang Li, Bailiang Wang, et al.. (2019). Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer. Molecular Cancer Therapeutics. 18(2). 399–412. 10 indexed citations

14.

Yang, Xiaosong, Pan You, Zhaojun Qiu, et al.. (2018). RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clinical Cancer Research. 24(7). 1629–1643. 30 indexed citations

15.

Haricharan, Svasti, Purba Singh, Kimberly R. Holloway, et al.. (2017). Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer Discovery. 7(10). 1168–1183. 50 indexed citations

16.

Lü, Jianfeng, Donna McEachern, Shunqiang Li, Matthew J. Ellis, & Shaomeng Wang. (2016). Reactivation of p53 by MDM2 Inhibitor MI-77301 for the Treatment of Endocrine-Resistant Breast Cancer. Molecular Cancer Therapeutics. 15(12). 2887–2893. 30 indexed citations

17.

Wardell, Suzanne E., Matthew J. Ellis, Holly M. Alley, et al.. (2015). Efficacy of SERD/SERM Hybrid-CDK4/6 Inhibitor Combinations in Models of Endocrine Therapy–Resistant Breast Cancer. Clinical Cancer Research. 21(22). 5121–5130. 115 indexed citations

18.

Xu, Siguang, Shunqiang Li, Zhanfang Guo, et al.. (2013). Combined Targeting of mTOR and AKT Is an Effective Strategy for Basal-like Breast Cancer in Patient-Derived Xenograft Models. Molecular Cancer Therapeutics. 12(8). 1665–1675. 41 indexed citations

19.

Bose, Ron, Shyam M. Kavuri, Adam C. Searleman, et al.. (2012). Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer. Cancer Discovery. 3(2). 224–237. 600 indexed citations breakdown →

20.

Tang, Yaxiong, Anne R. Simoneau, Yi Guo, et al.. (2009). WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G1 arrest and growth inhibition of human invasive urinary bladder cancer cells. Molecular Cancer Therapeutics. 8(2). 458–468. 89 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact